JP2009500427A5 - - Google Patents

Download PDF

Info

Publication number
JP2009500427A5
JP2009500427A5 JP2008520417A JP2008520417A JP2009500427A5 JP 2009500427 A5 JP2009500427 A5 JP 2009500427A5 JP 2008520417 A JP2008520417 A JP 2008520417A JP 2008520417 A JP2008520417 A JP 2008520417A JP 2009500427 A5 JP2009500427 A5 JP 2009500427A5
Authority
JP
Japan
Prior art keywords
group
disease
treating
medical condition
melanocortin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008520417A
Other languages
English (en)
Japanese (ja)
Other versions
JP4734411B2 (ja
JP2009500427A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/026586 external-priority patent/WO2007008704A2/en
Publication of JP2009500427A publication Critical patent/JP2009500427A/ja
Publication of JP2009500427A5 publication Critical patent/JP2009500427A5/ja
Application granted granted Critical
Publication of JP4734411B2 publication Critical patent/JP4734411B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008520417A 2005-07-08 2006-07-10 メラノコルチン受容体リガンド Active JP4734411B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US60/697,779 2005-07-08
US74885005P 2005-12-09 2005-12-09
US60/748,850 2005-12-09
PCT/US2006/026586 WO2007008704A2 (en) 2005-07-08 2006-07-10 Melanocortin receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009263603A Division JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド

Publications (3)

Publication Number Publication Date
JP2009500427A JP2009500427A (ja) 2009-01-08
JP2009500427A5 true JP2009500427A5 (https=) 2010-01-21
JP4734411B2 JP4734411B2 (ja) 2011-07-27

Family

ID=37637790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008520417A Active JP4734411B2 (ja) 2005-07-08 2006-07-10 メラノコルチン受容体リガンド
JP2009263603A Active JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Active JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009263603A Active JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Active JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Country Status (21)

Country Link
US (9) US8039435B2 (https=)
EP (6) EP2236151B1 (https=)
JP (4) JP4734411B2 (https=)
KR (2) KR101232201B1 (https=)
CN (5) CN119119190A (https=)
AU (2) AU2006269261B2 (https=)
BE (1) BE2021C557I2 (https=)
CA (4) CA2793119C (https=)
DK (4) DK2286825T3 (https=)
ES (4) ES2663916T3 (https=)
FR (1) FR21C1060I2 (https=)
HU (4) HUE055154T2 (https=)
IL (3) IL188545A (https=)
NL (1) NL301150I2 (https=)
NZ (2) NZ565217A (https=)
PL (4) PL2548568T3 (https=)
PT (4) PT2286825T (https=)
RU (2) RU2380372C2 (https=)
SG (1) SG163585A1 (https=)
SI (1) SI3354273T1 (https=)
WO (1) WO2007008704A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565217A (en) * 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
BRPI0819188B1 (pt) * 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina
CA2998948A1 (en) 2008-05-27 2009-12-17 Genzyme Corporation Peptide analogs of alpha-melanocyte stimulating hormone
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
US20120135923A1 (en) * 2009-08-05 2012-05-31 Ipsen Pharma, S.A.S. Use of Melanocortins to Treat Dyslipidemia
CN102574894A (zh) * 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
BR112013027222B1 (pt) * 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2668791C2 (ru) 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
EP2968475A2 (en) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物
EP2970388B1 (en) * 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
JP2017513875A (ja) 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体
PL3356386T3 (pl) * 2015-09-30 2024-08-05 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US10653743B2 (en) * 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US20200223889A1 (en) * 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
WO2019219714A1 (en) * 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
AU2019273132B2 (en) * 2018-05-23 2024-10-03 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
AU2021350017A1 (en) * 2020-09-24 2023-05-04 Rhythm Pharmaceuticals, Inc. Methods of treating melanocortin-4 receptor pathway-associated disorders
WO2022204305A2 (en) * 2021-03-24 2022-09-29 Glo Pharma, Inc. Peptides and methods for reducing skin pigmentation
EP4347019A4 (en) * 2021-05-27 2025-06-18 The Regents Of The University Of Michigan MC3R agonist peptides
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025123051A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain
WO2025245292A1 (en) * 2024-05-22 2025-11-27 Endevica Bio, Inc. Non-naturally occurring melanocortin receptor agonists and uses thereof for modulating weight loss
CN120699097A (zh) * 2024-09-03 2025-09-26 万邦德制药集团有限公司 一种二硫环肽化合物及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
EP1076649A4 (en) * 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
EP1100970A2 (en) * 1998-07-27 2001-05-23 Iowa State University Research Foundation, Inc. Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
CA2341903A1 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
ATE409410T1 (de) 1999-11-12 2008-10-15 Merck & Co Inc Zellen mit defizientem melanocortin-3-rezeptor, transgene mäuse und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
PL360855A1 (en) * 2000-06-28 2004-09-20 Pfizer Products Inc. Melanocortin receptor ligands
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
EP1322954A4 (en) 2000-09-13 2005-08-03 Eleanor Roosevelt Inst PROCESS FOR TREATING INSULIN RESISTANCE IN OBESITY AND DIABETES
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
CA2438272A1 (en) 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
EP1441750A4 (en) * 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
EP1644022A1 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
EP1658285B1 (en) * 2003-08-20 2007-05-02 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ATE350369T1 (de) * 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
CA2582607C (en) 2004-10-08 2016-07-12 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073772A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
NZ565217A (en) * 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
CN101273059B (zh) 2005-08-26 2014-02-19 艾伯维有限公司 治疗活性的α-MSH类似物

Similar Documents

Publication Publication Date Title
JP2009500427A5 (https=)
JP2010090130A5 (https=)
RU2009148318A (ru) Лиганды меланокортиновых рецепторов, модифицированные гидантоином
RU2401841C2 (ru) Лиганды рецепторов меланокортинов
RU2008104803A (ru) Лиганды рецепторов меланокортинов
TW200803862A (en) Compounds for modulating TRPV3 function
CN1309565A (zh) 用于治疗或预防睡眠障碍的药物组合物
JP2020100623A (ja) 炎症及び疼痛の治療のための組成物及び方法
KR102128810B1 (ko) 요산 또는 통풍 질환의 예방 또는 치료
JP2017507116A (ja) ｐ−置換非対称尿素及びその医薬的使用
WO2001022961A1 (en) New use of modafinil and the d/l enantiomer
US10604485B2 (en) Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea
EA014942B1 (ru) Соль глюкуроновой кислоты и соединения пиперазина
TW434015B (en) 4-aminopyrrole (3, 2-d) pyrimidines as neuropeptide Y receptor antagonists
US20120238616A1 (en) Methods and compositions for treating sleep-related breathing disorders
EP2451452B1 (en) Use of benzydamine in the treatment of p40-dependent diseases
CN114539130B (zh) 苯基哌嗪或苯基哌啶类化合物及其应用
CN109464583A (zh) 一种兽用抗炎中药组合物及其制备方法和应用
CN101262868B (zh) 包含哌嗪化合物的葡萄糖醛酸盐的持续释放制剂及其用途
RU2412184C2 (ru) Соли производного пиперазина с салициловой и гентизиновой кислотами
WO2022004788A1 (ja) 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤
CN101677556A (zh) 治疗cb2受体介导的疼痛的方法
CN106474113A (zh) 一种用于缺血性脑卒中后神经再生的药物组合物及其应用
CN104208507B (zh) 一种防治小儿惊风的穴位外敷膏
US20220402908A1 (en) Cxcr6 inhibitors and methods of use